Phillip P. Chan - 15 Sep 2026 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CTSO
Reported as of: 15 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2026, 17:30:30 UTC
Prior SEC filing: 09 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Phillip P. Chan

Key filing fact

Phillip P. Chan filed Form 4 for Cytosorbents Corp (CTSO) on 16 Sep 2026.

Key facts

This page summarizes Phillip P. Chan's Form 4 filing for Cytosorbents Corp (CTSO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 17:30.

Change

Previous filing in this sequence was filed on 09 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001442786 Primary reporting owner

Chan Phillip P.

Relationship: Chief Executive Officer, Director
Address: C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON
Signature: /s/ Phillip P. Chan
Signature date: 16 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Purchase

Transaction value
Shares: +3,774
Change %: +3.9%
Price: $6.00^*
Shares after: 100,996
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.

Footnote F2

Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 515 RSUs granted on March 15, 2018, (b) 935 RSUs granted on February 24, 2017, (c) 2,850 RSUs granted on June 7, 2016 and (d) 6,500 RSUs granted on April 8, 2015;

Footnote F3

(continued from footnote 2) (ii) 2,640 RSUs of 5,280 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 83,782 shares of Common Stock owned by the Reporting Person.

Footnote F4

Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.